Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary

Ascendis Pharma A/S

13/08/2026 14:31

Ascendis Pharma A/S ASND.OQ reported quarterly adjusted earnings of 72 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -64 cents.  The mean expectation of seventeen analysts for the quarter was for earnings of €1.38 per share. Wall Street expected results to range from 30 cents to €3.68 per share.
Revenue rose 114.7% to €339.29 million from a year ago; analysts expected €331.56 million. 
Ascendis Pharma A/S's reported EPS for the quarter was €2.83​.
The company reported quarterly net income of €206.97 million.
Ascendis Pharma A/S shares had fallen by 4.2% this quarter and gained 19.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 28.4% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Ascendis Pharma A/S is $305.50, about 16.4% above its last closing price of $255.46
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
1.38
0.72
Missed
Mar. 31 2026 
0.20
-0.77
Missed
Dec. 31 2025 
-0.04
-0.55
Missed
Sep. 30 2025 
-0.22
-1.00
Missed